Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Raised to “Buy” at JonesTrading

JonesTrading upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a buy rating in a report published on Wednesday, Marketbeat reports. They currently have $25.00 price objective on the biotechnology company’s stock.

Several other analysts have also recently commented on CAPR. Piper Sandler raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, September 1st. HC Wainwright lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, July 27th. Ladenburg Thalmann & Co. Inc. downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, July 30th. Oppenheimer restated an “outperform” rating on shares of Capricor Therapeutics in a research report on Thursday, October 8th. Finally, Roth Capital lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price objective for the company. in a research report on Monday, July 27th. Five analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $29.77.

Capricor Therapeutics Stock Up 26.5%

Capricor Therapeutics stock opened at $11.22 on Wednesday. The company has a 50 day moving average price of $8.09 and a 200 day moving average price of $19.99. Capricor Therapeutics has a 52 week low of $2.96 and a 52 week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.29). Research analysts predict that Capricor Therapeutics will post -1.71 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. Activest Wealth Management grew its position in Capricor Therapeutics by 100.0% in the third quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 2,000 shares in the last quarter. KBC Group NV acquired a new position in shares of Capricor Therapeutics during the 1st quarter worth $44,000. Russell Investments Group Ltd. raised its holdings in shares of Capricor Therapeutics by 21.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 3,036 shares in the last quarter. VestGen Advisors LLC bought a new position in shares of Capricor Therapeutics during the 3rd quarter valued at $191,000. Finally, SBI Securities Co. Ltd. raised its holdings in shares of Capricor Therapeutics by 834.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 23,495 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

Top Capricor Therapeutics Stories

Here are a few of the latest stories about CAPR:

• Positive Sentiment: JonesTrading upgraded Capricor from “hold” to “buy” and set a $25 price target, citing potential upside from the share price referenced in the report. TickerReport article
• Neutral Sentiment: The company outlined manufacturing validation work planned for 2027. This provides a view of its preparations, though successful execution and the FDA outcome remain important uncertainties. Seeking Alpha article
• Negative Sentiment: Capricor reported a third-quarter loss of $0.73 per share, wider than the $0.44 loss analysts expected. The company also cut its workforce by 10%, underscoring ongoing financial and operational pressures. Capricor earnings release

About Capricor Therapeutics

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.